Literature DB >> 11146471

Mapping of the autosomal recessive (AR) craniometaphyseal dysplasia locus to chromosome region 6q21-22 and confirmation of genetic heterogeneity for mild AR spondylocostal dysplasia.

P Iughetti1, L G Alonso, W Wilcox, N Alonso, M R Passos-Bueno.   

Abstract

We report on a four-generation inbred family including 10 individuals affected with a form of craniotubular dysplasia (CTD). All affected patients were born to consanguineous healthy parents; this finding, together with the equal sex ratio among affected individuals and the occurrence of only normal individuals among their offspring, indicates that the disease in this family is an autosomal recessive (AR) trait. Taking into account the segregation pattern of the disease in the family and the radiological characteristics of two young CTD patients, the most likely diagnosis for the defect is AR craniometaphyseal dysplasia (CMD). CMD is a CTD, with both autosomal dominant (AD) and recessive forms. The description of the present genealogy confirms the AR pattern of inheritance of some cases of CMD and contributes to a better delineation of the clinical spectrum of AR CMD, suggesting a more pronounced diaphyseal involvement in the AR compared with the AD CMD. Through genomewide scanning, we mapped the AR CMD to a 7 cM interval, between D6S302 and D6S1639, at 6q21-22 region. We have also excluded the positional candidate COL10A1 gene as being the responsible for this disorder. Curiously, a form of AR spondylocostal dysplasia (SD) also segregates in the family, including one affected individual with both conditions. The gene DLL3, mapped to 19q13 region, was recently found to be responsible for one form of AR SD; however, we did not find evidence of linkage between this 19q region and the SD segregating in our family, thus implying in genetic heterogeneity for AR SD. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11146471     DOI: 10.1002/1096-8628(20001218)95:5<482::aid-ajmg14>3.0.co;2-x

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

1.  Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK.

Authors:  E Reichenberger; V Tiziani; S Watanabe; L Park; Y Ueki; C Santanna; S T Baur; R Shiang; D K Grange; P Beighton; J Gardner; H Hamersma; S Sellars; R Ramesar; A C Lidral; A Sommer; C M Raposo do Amaral; R J Gorlin; J B Mulliken; B R Olsen
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

2.  Vgll2a is required for neural crest cell survival during zebrafish craniofacial development.

Authors:  Christopher W Johnson; Laura Hernandez-Lagunas; Weiguo Feng; Vida Senkus Melvin; Trevor Williams; Kristin Bruk Artinger
Journal:  Dev Biol       Date:  2011-06-30       Impact factor: 3.582

3.  A genome-wide linkage scan for quantitative trait loci influencing the craniofacial complex in humans (Homo sapiens sapiens).

Authors:  Richard J Sherwood; Dana L Duren; Michael C Mahaney; John Blangero; Thomas D Dyer; Shelley A Cole; Stefan A Czerwinski; Wm Cameron Chumlea; Roger M Siervogel; Audrey C Choh; Ramzi W Nahhas; Miryoung Lee; Bradford Towne
Journal:  Anat Rec (Hoboken)       Date:  2011-02-15       Impact factor: 2.064

Review 4.  The Erlenmeyer flask bone deformity in the skeletal dysplasias.

Authors:  Maha A Faden; Deborah Krakow; Fatih Ezgu; David L Rimoin; Ralph S Lachman
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

5.  An atypical case of craniometaphyseal dysplasia. Case report and surgical treatment.

Authors:  Giorgio Novelli; Emanuela Ardito; Fabio Mazzoleni; Alberto Bozzetti; Davide Sozzi
Journal:  Ann Stomatol (Roma)       Date:  2017-11-08

6.  A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia.

Authors:  Ying Hu; I-Ping Chen; Salome de Almeida; Valdenize Tiziani; Cassio M Raposo Do Amaral; Kalpana Gowrishankar; Maria Rita Passos-Bueno; Ernst J Reichenberger
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.